Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK010 or NK042 + Rituximab in Refractory SLE or LN
NCT06676631Phase 1Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK010 and NK042 in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Response rate for SLE response index 4 at 12 months, Number of participants who achieved renal response at 12 months and 7 more. Started Feb 2025; status: recruiting.
02
Drugs
NK010NK042
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT06676631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676631.